Institution
Chinese PLA General Hospital
Also known as: 301 Military Hospital · 中国人民解放军总医院 · PLAGH
- 141running trials
- 51closed trials
- 0trials confirmed by the site in the last 60 days
- –languages not stated
No trial has been confirmed here yet.
Running trials
Recruiting
Not yet recruiting
BCMA/GPRC5D Dual-Target CAR-T Cell Immunotherapy for Relapsed/Refractory Multiple Myeloma
Not yet recruiting
CLL-1/CD70 Dual-Target CAR-T Cell Therapy for Acute Myeloid Leukemia
Not yet recruiting
A Phase 3 Study of Deutenzalutamide in Patients With High-Risk BCR Prostate Cancer
Not yet recruiting
Not yet recruiting
Not yet recruiting
CLL-1-Targeted In Vivo CAR-T Cell Immunotherapy for Relapsed/Refractory Acute Myeloid Leukemia
Not yet recruiting
PCSK9 Inhibitor for Intracranial Atherosclerosis Related Acute Ischemic Stroke
Recruiting
Recruiting
Active, not recruiting
Study of the Beach Regimen on Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)
Not yet recruiting
Platform Research for Innovative Medicines in NF2-SWN (PRIME-NF2)
Not yet recruiting
Recruiting
Not yet recruiting
Recruiting
Effect of the Traditional Chinese Medicine Yufeng Ningxin in Patients With Hypertension
Not yet recruiting
The Safety and Efficacy of KSVCBD Injection in Neuromyelitis Optica Spectrum Disorder.
Recruiting
Not yet recruiting
Predictive Role of Photon Counting Computed Tomography in Acute Coronary Syndrom Patients
Recruiting
Recruiting
Multicenter Validation of the 2025 Classification Criteria for Axial Spondyloarthritis
Not yet recruiting
Chronic Kidney Disease and Metabolic Disorders in the Elderly
Recruiting
A Study of HDM1005 in Participants With Type 2 Diabetes Not Controlled With Diet and Exercise Alone
Enrolling by invitation
Not yet recruiting
Enrolling by invitation
Recruiting
Not yet recruiting
Recruiting
CD19/CD22 CAR-T as First-line Consolidation in Follicular Lymphoma
Recruiting
Targeted CD22/CD19 CAR-T Therapy for Consolidation in Standard-Risk B-ALL
Recruiting
Recruiting
Recruiting
IBI351 Plus Cetuximab β in Untreated Advanced Non-small Cell Lung Cancer With KRAS G12C Mutation
Recruiting
Recruiting
Early Application of Budesonide Enteric-coated Capsules in the Treatment of Primary IgA Nephropathy.
Recruiting
Exploratory Study of Personalized mRNA Vaccine in Patients With Refractory Rhabdomyosarcoma
Recruiting
Study of PD-1Ab21-BCMA CAR-T Therapy for Consolidation of Multiple Myelomawith Renal Dysfunction
Recruiting
Recruiting
Recruiting
Recruiting
Recruiting
Pegmolesatide Treatment for Anemia in Patients Undergoing Long-term Dialysis
Recruiting
Alzheimer's Disease Multinuclear Imaging Neuro-Enhanced Resolution (AD-MINER)
Recruiting
Recruiting
Recruiting
Safety and Efficacy of Mesenchymal Stromal Cells (Amimestrocel ) in Diabetic Kidney Disease
Active, not recruiting
Maintenance Therapy With Selinexor and Azacitidine in TP53 Mutant AML/MDS After Transplantation
Recruiting
Recruiting
Active, not recruiting
Showing 50 of 141.
Recruiting at the same time
How many trials recruit for the same indication here at once. A count, not a rating.
- Liver and biliary tract cancer16 recruiting
- Childhood cancers15 recruiting
- Acute myeloid leukaemia11 recruiting
- Chronic kidney disease11 recruiting
- Alzheimer disease7 recruiting
- Colorectal cancer7 recruiting
- Gastric and oesophageal cancer7 recruiting
- Acute lymphoblastic leukaemia6 recruiting
- Coronary artery disease5 recruiting
- Lung cancer4 recruiting
- Stroke4 recruiting
- Prostate cancer3 recruiting
- Thyroid cancer3 recruiting
- Type 2 diabetes3 recruiting
- Ankylosing spondylitis2 recruiting
- Glioblastoma2 recruiting
- High blood pressure2 recruiting
- Multiple myeloma2 recruiting
- Myelodysplastic syndromes2 recruiting
- Neuroendocrine tumours2 recruiting
- Pancreatic cancer2 recruiting
- Parkinson disease2 recruiting
- ANCA-associated vasculitis1 recruiting
- Diffuse large B-cell lymphoma1 recruiting
- Epilepsy1 recruiting
- Follicular lymphoma1 recruiting
- Hodgkin lymphoma1 recruiting
- IgA nephropathy1 recruiting
- Kidney cancer1 recruiting
- Neuromyelitis optica (NMOSD)1 recruiting
- Obesity1 recruiting
- Pompe disease1 recruiting
- Sarcoma1 recruiting
Researchers
No researcher is linked here yet.
Closed trials
Completed
Completed
A Trial of HRS-7535 Tablets in Subjects With Overweight or Obesity
Completed
Completed
Different Cycles of Neoadjuvant PD-1 Blockades + Chemotherapy for Advanced Gastric Cancer
Completed
Long-term Efficacy and Safety of HRS-7535 Tablets in Obese Subjects
Completed
Study of Oral Atogepant Tablets to Assess Safety and Efficacy in Adult Participants With Migraine
Completed
A Phase I Clinical Study on the Safety and Pharmacokinetics of [18F]Florbetazine Injection
Completed
Completed
A Study of Tirzepatide (LY3298176) in Chinese Participants With Type 2 Diabetes (SURPASS-CN-MONO)
Completed
Completed
Completed
A Study of Orforglipron in Adult Participants With Obesity or Overweight and Type 2 Diabetes
Completed
A Study to Learn About the Safety and Effects of Rimegepant to Prevent Migraine in Chinese Subjects.
Completed
A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome
Completed
Venetoclax Plus CACAG Regimen for Newly Diagnosed Acute Myeloid Leukemia
Completed
Completed
Completed
Completed
Surufatinib Plus Anti-PD-1/L1 as Maintenance Therapy in Extensive-Stage Small Cell Lung Cancer
Completed
Completed
A Study of PM8002 Injection in Combination With Standard Chemotherapy as First Line Therapy in MPM
Terminated
Completed
Completed
Terminated
GPC3-targeting CART Cell in Treatment of Advanced Hepatocellular Carcinoma
Completed
Adjunctive GNX Treatment Compared With Placebo in Children and Adults With TSC-related Epilepsy
Completed
Completed
Compare the Efficacy and Safety of HLX04-O with Ranibizumab in Subjects with WAMD
Completed
CEND-1 Injection (QLC12102) in Patients With Advanced Metastatic Pancreatic Ductal Adenocarcinoma
Completed
Completed
GB491 Combined With Fulvestrant for HR+ HER2- Locally Advanced or Metastatic Breast Cancer
Completed
Completed
Efficacy and Safety of SHR-1314 in Patients With Active Ankylosing Spondylitis
Completed
Completed
Completed
Completed
Completed
Completed
Completed
Completed
Completed
Completed
Completed
Terminated
A Study of Anti-PD-1 AK105 in Patients With Metastatic Nonsquamous Non-small Cell Lung Cancer
Completed
Completed
Completed
Completed
Completed
Showing 50 of 51.
Trial sites
- Chinese PLA General Hospital174 trials
- Chinese PLA General Hospital, Beijing,6 trials
- Chinese PLA General Hospital, Beijing, Beijing 1008531 trial
- Chinese PLA general hospital, Beijing, China1 trial
- Chinese PLA General Hospital /ID# 2067861 trial
- Chinese PLA General Hospital /ID# 2162861 trial
- Chinese PLA General Hospital /ID# 2575401 trial
- Chinese PLA General Hospital /ID# 2671411 trial
- Chinese PLA General Hospital/Oncology1 trial
- Department of Biotherapeutic, Chinese PLA General Hospital1 trial
- Department of Hematology, Chinese PLA General Hospital1 trial
- Chinese PLA General Hospital3 trials
Conditions
Diseases this institution publishes on or runs trials for.
- Liver and biliary tract cancer186 works · 23 trials
- Lung cancer129 works · 11 trials
- Stroke125 works · 5 trials
- Gastric and oesophageal cancer77 works · 14 trials
- Colorectal cancer73 works · 8 trials
- Chronic kidney disease70 works · 13 trials
- Kidney cancer49 works · 1 trial
- Prostate cancer48 works · 5 trials
- Tuberculosis44 works · 0 trials
- Osteoporosis39 works · 0 trials
- Migraine36 works · 6 trials
- Coronary artery disease34 works · 12 trials
- Hepatitis B32 works · 0 trials
- Bladder cancer28 works · 1 trial
- Glioblastoma27 works · 2 trials
- COPD26 works · 0 trials
- Acute myeloid leukaemia21 works · 17 trials
- Thyroid cancer16 works · 3 trials
- ALS (motor neurone disease)15 works · 0 trials
- Ankylosing spondylitis11 works · 3 trials
- IgA nephropathy9 works · 1 trial
- Myelodysplastic syndromes9 works · 3 trials
- Duchenne muscular dystrophy6 works · 1 trial
- Pompe disease6 works · 1 trial
- Neuromyelitis optica (NMOSD)5 works · 1 trial
- Primary biliary cholangitis4 works · 0 trials
Institution data: ROR 04gw3ra78 (CC0-1.0)Updated 10 Nov 2026